Ocumension Therapeutics announced the completion of patient enrollment in the real-world study of OT-703 (ILUVIEN®, fluocinolone intravitreal implant) in the Boao Lecheng International Medical Tourism Pilot Zone, Hainan Province, China. The study enrolled a total of 195 patients with diabetic macular edema (DME). OT-703 is a 190 microgram fluocinolone acetonide intravitreal implant designed to deliver sustained release of the corticosteroid for up to 36 months. The company previously obtained exclusive rights to develop and commercialize ILUVIEN® in Greater China, South Korea, and 11 Southeast Asian countries. The results of the real-world study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260120-11995316), on January 19, 2026, and is solely responsible for the information contained therein.